Enimmune Corporation (TPEX:6564)
Taiwan · Delayed Price · Currency is TWD 19.95
+0.15 (0.76%)
At close: Feb 11, 2026
Enimmune Revenue
Enimmune had revenue of 22.64M TWD in the half year ending June 30, 2025, with 74.18% growth. This brings the company's revenue in the last twelve months to 42.23M, down -16.90% year-over-year. In the year 2024, Enimmune had annual revenue of 39.92M, down -8.23%.
Revenue (ttm)
42.23M
Revenue Growth
-16.90%
P/S Ratio
33.82
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 39.92M | -3.58M | -8.23% |
| Dec 31, 2023 | 43.49M | -144.92M | -76.92% |
| Dec 31, 2022 | 188.42M | 78.59M | 71.56% |
| Dec 31, 2021 | 109.82M | 86.95M | 380.08% |
| Dec 31, 2020 | 22.88M | 20.93M | 1,076.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genomics BioSci & Tech. | 607.89M |
| Meribank Biotech | 486.52M |
| GenMont Biotech Incorporation | 391.48M |
| Abnova (Taiwan) | 355.40M |
| GeneReach Biotechnology | 215.32M |
| NeoCore Technology | 190.10M |
| Lukas Biomedical | 180.32M |
| Holy Stone Healthcare | 47.51M |